Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 9;14(8):841.
doi: 10.3390/jpm14080841.

Innovative Implementation Strategies for Familial Hypercholesterolemia Cascade Testing: The Impact of Genetic Counseling

Kelly M Morgan  1 , Gemme Campbell-Salome  1   2 , Nicole L Walters  1 , Megan N Betts  3 , Andrew Brangan  1 , Alicia Johns  4 , H Lester Kirchner  2 , Zoe Lindsey-Mills  1 , Mary P McGowan  5 , Eric P Tricou  5 , Alanna Kulchak Rahm  1 , Amy C Sturm  1   6   7 , Laney K Jones  1   6
Affiliations

Innovative Implementation Strategies for Familial Hypercholesterolemia Cascade Testing: The Impact of Genetic Counseling

Kelly M Morgan et al. J Pers Med. .

Abstract

The IMPACT-FH study implemented strategies (packet, chatbot, direct contact) to promote family member cascade testing for familial hypercholesterolemia (FH). We evaluated the impact of genetic counseling (GC) on medical outcomes, strategy selection, and cascade testing. Probands (i.e., patients with FH) were recommended to complete GC and select sharing strategies. Comparisons were performed for both medical outcomes and strategy selection between probands with or without GC. GEE models for Poisson regression were used to examine the relationship between proband GC completion and first-degree relative (FDR) cascade testing. Overall, 46.3% (81/175) of probands completed GC. Probands with GC had a median LDL-C reduction of -13.0 mg/dL (-61.0, 4.0) versus -1.0 mg/dL (-16.0, 17.0) in probands without GC (p = 0.0054). Probands with and without GC selected sharing strategies for 65.3% and 40.3% of FDRs, respectively (p < 0.0001). Similarly, 27.1% of FDRs of probands with GC completed cascade testing, while 12.0% of FDRs of probands without GC completed testing (p = 0.0043). Direct contact was selected for 47 relatives in total and completed for 39, leading to the detection of 18 relatives with FH. Proband GC was associated with improved medical outcomes and increased FDR cascade testing. Direct contact effectively identified FH cases for the subset who participated.

Keywords: cascade testing; familial hypercholesterolemia; genetic counseling; population genomic screening.

PubMed Disclaimer

Conflict of interest statement

Kelly M. Morgan, Nicole L. Walters, Gemme Campbell-Salome, Megan N. Betts, Eric P. Tricou, Andrew Brangan, Zoe Lindsey-Mills, Alicia Johns, H. Lester Kirchner, and Alanna Kulchak Rahm declare no conflicts of interest. Mary P. McGowan: Advisory board for Novartis. Amy C. Sturm: Employee and Shareholder of 23andMe, Advisor to Nest Genomics. Laney K. Jones: Consultant for Novartis. The sponsor had no role in the design, execution, interpretation, or writing of the study.

Figures

Figure 1
Figure 1
Overview of Results Disclosure, Genetic Counseling, and Study Follow-up.
Figure 2
Figure 2
Direct Contact Uptake and Outcomes. 1 Three outreach attempts; 2 Two relatives declined genetic testing during DC, and one relative did not complete the genetic testing that was ordered during DC.
See this image and copyright information in PMC

References

    1. Nordestgaard B.G., Chapman M.J., Humphries S.E., Ginsberg H.N., Masana L., Descamps O.S., Wiklund O., Hegele R.A., Raal F.J., Defesche J.C., et al. European Atherosclerosis Society Consensus Panel, Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease: Consensus statement of the European Atherosclerosis Society. Eur. Heart J. 2013;34:3478–3490a. - PMC - PubMed
    1. Grundy S.M., Stone N.J., Bailey A.L., Beam C., Birtcher K.K., Blumenthal R.S., Braun L.T., De Ferranti S., Faiella-Tommasino J., Forman D.E., et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082–e1143. - PMC - PubMed
    1. Luirink I.K., Wiegman A., Kusters D.M., Hof M.H., Groothoff J.W., de Groot E., Kastelein J.J.P., Hutten B.A. 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. N. Engl. J. Med. 2019;381:1547–1556. doi: 10.1056/NEJMoa1816454. - DOI - PubMed
    1. Nordestgaard B.G., Benn M. Genetic testing for familial hypercholesterolaemia is essential in individuals with high LDL cholesterol: Who does it in the world? Eur. Heart J. 2017;38:1580–1583. doi: 10.1093/eurheartj/ehx136. - DOI - PubMed
    1. Tada H., Kawashiri M.A., Nohara A., Sekiya T., Watanabe A., Takamura M. Genetic Counseling and Genetic Testing for Familial Hypercholesterolemia. Genes. 2024;15:297. doi: 10.3390/genes15030297. - DOI - PMC - PubMed

LinkOut - more resources